Detalles de la búsqueda
1.
Clinico-Immunological Effects of a Single-Agent CDK4/6 Inhibitor in Advanced HR+/HER2- Breast Cancer Based on a Window of Opportunity Study.
Curr Issues Mol Biol
; 44(9): 4255-4267, 2022 Sep 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-36135204
2.
Immune system and angiogenesis-related potential surrogate biomarkers of response to everolimus-based treatment in hormone receptor-positive breast cancer: an exploratory study.
Breast Cancer Res Treat
; 184(2): 421-431, 2020 Nov.
Artículo
en Inglés
| MEDLINE | ID: mdl-32770287
3.
Could gonadotropin-releasing hormone analogs be helpful in the treatment of triple-negative breast cancer?
Future Oncol
; 13(27): 2473-2477, 2017 Nov.
Artículo
en Inglés
| MEDLINE | ID: mdl-29121807
4.
A Phase II study of olaparib in breast cancer patients: biological evaluation from a 'window of opportunity' trial.
Future Oncol
; 12(19): 2189-93, 2016 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-27324108
5.
Pure anti-tumor effect of zoledronic acid in naïve bone-only metastatic and locally advanced breast cancer: proof from the "biological window therapy".
Breast Cancer Res Treat
; 144(1): 113-21, 2014 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-24469643
6.
Prediction of response to neoadjuvant chemotherapy by MammaTyper® across breast cancer subtypes: A retrospective cross-sectional study.
Breast
; 76: 103753, 2024 May 25.
Artículo
en Inglés
| MEDLINE | ID: mdl-38815444
7.
Faecal microbiota composition is related to response to CDK4/6-inhibitors in metastatic breast cancer: A prospective cross-sectional exploratory study.
Eur J Cancer
; 191: 112948, 2023 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-37454444
8.
Computational reactive-diffusive modeling for stratification and prognosis determination of patients with breast cancer receiving Olaparib.
Sci Rep
; 13(1): 11951, 2023 07 24.
Artículo
en Inglés
| MEDLINE | ID: mdl-37488154
9.
Real-world ANASTASE study of atezolizumab+nab-paclitaxel as first-line treatment of PD-L1-positive metastatic triple-negative breast cancer.
NPJ Breast Cancer
; 9(1): 73, 2023 Sep 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-37684252
10.
Tumor Type Agnostic Therapy Carrying BRAF Mutation: Case Reports and Review of Literature.
Pharmaceuticals (Basel)
; 14(2)2021 Feb 16.
Artículo
en Inglés
| MEDLINE | ID: mdl-33669326
11.
Clinical, Radiometabolic and Immunologic Effects of Olaparib in Locally Advanced Triple Negative Breast Cancer: The OLTRE Window of Opportunity Trial.
Front Oncol
; 11: 686776, 2021.
Artículo
en Inglés
| MEDLINE | ID: mdl-34262869
12.
COVID-19 in breast cancer patients: a subanalysis of the OnCovid registry.
Ther Adv Med Oncol
; 13: 17588359211053416, 2021.
Artículo
en Inglés
| MEDLINE | ID: mdl-34777582
13.
Impact of BMI on the outcome of metastatic breast cancer patients treated with everolimus: a retrospective exploratory analysis of the BALLET study.
Oncotarget
; 11(23): 2172-2181, 2020 Jun 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-32577163
14.
Early Changes of the Standardized Uptake Values (SUVmax) Predict the Efficacy of Everolimus-Exemestane in Patients with Hormone Receptor-Positive Metastatic Breast Cancer.
Cancers (Basel)
; 12(11)2020 Nov 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-33182575
15.
Bone metastases from primary cardiac sarcoma: case report.
Tumori
; 95(2): 251-3, 2009.
Artículo
en Inglés
| MEDLINE | ID: mdl-19579876
16.
Author Correction: Real-world ANASTASE study of atezolizumab+nab-paclitaxel as first-line treatment of PD-L1-positive metastatic triple-negative breast cancer.
NPJ Breast Cancer
; 10(1): 13, 2024 Feb 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-38316819
17.
Benefit of the addition of hormone therapy to neoadjuvant anthracycline-based chemotherapy for breast cancer: comparison of predicted and observed pCR.
J Cancer Res Clin Oncol
; 144(3): 601-606, 2018 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-29344722
18.
Author Correction: Real-world ANASTASE study of atezolizumab+nab-paclitaxel as first-line treatment of PD-L1-positive metastatic triple-negative breast cancer.
NPJ Breast Cancer
; 9(1): 89, 2023 Oct 30.
Artículo
en Inglés
| MEDLINE | ID: mdl-37903774
19.
Addendum: Impact of BMI on the outcome of metastatic breast cancer patients treated with everolimus: a retrospective exploratory analysis of the BALLET study.
Oncotarget
; 13: 1307, 2022 Dec 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-36473136
20.
Hypoxia-related biological markers as predictors of epirubicin-based treatment responsiveness and resistance in locally advanced breast cancer.
Oncotarget
; 8(45): 78870-78881, 2017 Oct 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-29108271